Addex Therapeutics Ltd. (ADXN): Financial results for H1 2026
Addex Therapeutics Ltd. (ADXN) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical co
How this was made
The 30-second read
Why it matters
The earnings release provides the first public disclosure of the half‑year financials, showing a deeper loss and cash decline, which is likely to depress the share price.
Market read
Micro‑cap biotech earnings with cash burn concerns; relevant for traders tracking small‑cap ADRs.
What to watch
Potential upside from regained GABAB program rights and upcoming Phase 1 data from Neurosterix.
Background
Addex Therapeutics is a clinical‑stage biopharma listed on SIX and NASDAQ (ADR).
Ticker impact
Addex Therapeutics reported H1 2026 results with a net loss of CHF 1.745 million and cash reduced to CHF 0.8 million, indicating continued cash burn.
likely pressure as investors price in the loss and cash depletion
The disclosed loss and shrinking cash position are material new information for a micro‑cap biotech, prompting sell‑side sentiment.
Market effects
Highlights ongoing funding challenges for small‑cap neuro‑pharma companies.
May weigh on Swiss biotech listings and ADRs in the US.
Limited to niche biotech investors.
Counterpoint
If the cash raise via ATM and rights regain are viewed as runway, the stock could be undervalued.
Key entities
- companyAddex Therapeutics Ltd.
Clinical‑stage biopharma developing allosteric modulators.
- executiveTim Dyer
CEO of Addex Therapeutics.